Dr. Welslau on the Benefits of Biosimilars in DLBCL

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses​ the potential benefits of ​using biosimilars in diffuse large B-cell lymphoma (DLBCL).

Due to low​er market price​s, biosimilars offer a more accessible ​options to patients in ​developed and underdeveloped countries, Welslau explains.

Notably, biosimilars have a different approval process compared with biologics​, says Welslau. If the biosimilar agentdemonstrates clinical similarity to the reference biologic and does not demonstrate clinically meaningful differences regarding safety and efficacy, only 1 confirmatory phase 3 study is required to receive FDA and European Medicines Agency approval, Welslau concludes.